Given that prion disease has heterogeneous subtypes with distinct rates of progression7, the difference between a half-life of <1 day versus 5 days would have a dramatic impact on the inclusion criteria needed to select for patients likely to have time to benefit from a PrP-lowering drug in clinical trials. The gene discussed is PRNP; the disease is prion disease.